What was the primary driver of Pfizer's revenue growth in the first nine months of 1999?

Pfizer's revenue growth was primarily driven by its Pharmaceutical segment, which saw a significant increase in worldwide revenues due to the strong performance of its key products such as Norvasc, Zithromax, and Viagra, as well as substantial growth in alliance revenues from co-promoted products like Celebrex.

What impact did the Trovan inventory write-off have on Pfizer's financial results?

The Trovan inventory write-off resulted in a pre-tax charge of $310 million recorded in the third quarter of 1999. This significantly impacted the Cost of Sales and consequently reduced net income and earnings per share for both the third quarter and the nine-month period.

How has Pfizer's financial position changed in terms of liquidity and debt?

Pfizer's financial position saw an increase in short-term borrowings to $5.49 billion, primarily used to fund common stock purchases and investments. This led to a decrease in working capital and a higher debt-to-total capitalization ratio. Consequently, cash and cash equivalents decreased to $942 million, while short-term investments increased.

What are the key ongoing legal matters that investors should be aware of?

Investors should be aware of ongoing legal proceedings including patent infringement suits related to nifedipine (Procardia XL) and doxazosin (Cardura), an antitrust investigation by the FTC, a trademark infringement litigation concerning the TROVAN mark resulting in a substantial jury award, and various product liability claims, such as those related to Shiley heart valves and asbestos exposure. While the company believes most of these will not materially affect its financial position, they represent potential risks.

PFE 10-Q Filed Nov 15, 1999

Summary

Pfizer Inc. reported strong revenue growth for the nine months ended October 3, 1999, with total revenues increasing by 21% to $11.7 billion compared to the same period in 1998. This growth was primarily driven by the pharmaceutical segment, which saw a 23% increase in worldwide revenues to $10.77 billion, fueled by key products like Norvasc, Zithromax, and Viagra, as well as significant growth in alliance revenue from co-promoted products. The company also experienced robust growth in its Animal Health segment. Despite the strong top-line performance, net income for the nine months declined by 18% to $2.23 billion, largely impacted by a significant $310 million pre-tax charge for writing off Trovan inventories due to regulatory actions and a shift in accounting for inventories from LIFO to FIFO. The balance sheet shows a healthy increase in total assets to $20.24 billion, though short-term borrowings saw a substantial increase to fund share repurchases and investments. The company is actively pursuing strategic growth opportunities, including a proposal to acquire Warner-Lambert, indicating a forward-looking approach to market expansion and product portfolio enhancement.

Key Highlights

1Total revenues for the nine months ended October 3, 1999, grew 21% year-over-year to $11.7 billion, driven by strong performance in the Pharmaceutical and Animal Health segments.
2Pharmaceutical segment revenues increased 23% to $10.77 billion for the nine-month period, supported by key products and growing alliance revenues from co-promoted drugs like Celebrex.
3A $310 million pre-tax charge was recorded in the third quarter for the write-off of Trovan inventories due to regulatory suspensions, negatively impacting net income.
4Net income for the nine months decreased 18% to $2.23 billion, primarily due to the Trovan inventory charge and the absence of significant gains from discontinued operations seen in the prior year.
5The company's balance sheet reflects increased short-term borrowings of $5.49 billion, largely to fund share repurchases and investments, while cash and cash equivalents decreased to $942 million.
6Pfizer announced a proposal to acquire Warner-Lambert Company in early November 1999, signaling a significant strategic move for future growth and market consolidation.
7Research and Development expenses increased by 27% for the nine months, underscoring Pfizer's commitment to innovation and pipeline development.

PFIZER INC Quarterly Report for Q3 Ended Oct 3, 1999

Summary

Key Highlights

Frequently Asked Questions